Search research articles
Contact Us
Filters
Showing results (161-170 of 207) with videos related to
Page
of 21
Sort By:
Sarcoma
|
June 19, 2023
Fibroblast Activation Protein Expression in Sarcomas
Jacquelyn N Crane, Danielle S Graham, Christine E Mona, et al.
European Urology
|
March 19, 2023
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)
Robert Seifert, Louise Emmett, Steven P Rowe, et al.
Cancer
|
October 18, 2025
Prostate-specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long-term survival
Kemal Caglar Gogebakan, Zizi Elsisi, Felipe Montano-Campos, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 17, 2021
Head-to-head intra-individual comparison of biodistribution and tumor uptake of <sup>68</sup>Ga-FAPI and <sup>18</sup>F-FDG PET/CT in cancer patients
Frederik L Giesel, Clemens Kratochwil, Joel Schlittenhardt, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 4, 2025
Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [<sup>177</sup>Lu]Lu-PSMA-617: A Single-Center Retrospective Study
Vishnu Murthy, Koichiro Kimura, Lela Theus, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 30, 2021
A Comprehensive Assessment of <sup>68</sup>Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients
Monica Abghari-Gerst, Wesley R Armstrong, Kathleen Nguyen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 5, 2020
Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer
Andreea D Stuparu, Joseph R Capri, Catherine A L Meyer, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 11, 2026
Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [<sup>177</sup>Lu]Lu-PSMA-617 or [<sup>177</sup>Lu]Lu-PSMA-I&T therapy: dosimetry results
Josef Zahner, Astrid Delker, Zachary Ells, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 19, 2020
False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial
Wolfgang P Fendler, Jeremie Calais, Matthias Eiber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 16, 2017
Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence
Jeremie Calais, Wolfgang P Fendler, Matthias Eiber, et al.
Page
of 21
Search research articles
Search
Showing results (161-170 of 207) with videos related to
Sort By:
Page
of 21
Sarcoma
|
June 19, 2023
Fibroblast Activation Protein Expression in Sarcomas
Jacquelyn N Crane, Danielle S Graham, Christine E Mona, et al.
European Urology
|
March 19, 2023
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)
Robert Seifert, Louise Emmett, Steven P Rowe, et al.
Cancer
|
October 18, 2025
Prostate-specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long-term survival
Kemal Caglar Gogebakan, Zizi Elsisi, Felipe Montano-Campos, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 17, 2021
Head-to-head intra-individual comparison of biodistribution and tumor uptake of <sup>68</sup>Ga-FAPI and <sup>18</sup>F-FDG PET/CT in cancer patients
Frederik L Giesel, Clemens Kratochwil, Joel Schlittenhardt, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 4, 2025
Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [<sup>177</sup>Lu]Lu-PSMA-617: A Single-Center Retrospective Study
Vishnu Murthy, Koichiro Kimura, Lela Theus, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 30, 2021
A Comprehensive Assessment of <sup>68</sup>Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients
Monica Abghari-Gerst, Wesley R Armstrong, Kathleen Nguyen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 5, 2020
Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer
Andreea D Stuparu, Joseph R Capri, Catherine A L Meyer, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 11, 2026
Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [<sup>177</sup>Lu]Lu-PSMA-617 or [<sup>177</sup>Lu]Lu-PSMA-I&T therapy: dosimetry results
Josef Zahner, Astrid Delker, Zachary Ells, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 19, 2020
False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial
Wolfgang P Fendler, Jeremie Calais, Matthias Eiber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 16, 2017
Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence
Jeremie Calais, Wolfgang P Fendler, Matthias Eiber, et al.
Page
of 21